Skip Ribbon Commands
Skip to main content
Menu

Guide to Peptide Receptor Radionuclide Therapy (PRRT)

Peptide Receptor Radionuclide Therapy (PRRT) is a treatment that targets certain types of neuroendocrine or somatostatin receptor positive tumours. This guide aims to provide patients and their families with essential information about the procedure, its administration, and post-treatment care.

Treatment Procedure:

PRRT involves the administration of a radioactive medication through intravenous infusion. Two intravenous cannulas will be inserted: one for hydration with amino acids to protect your kidneys, and another for the radioactive medication. A urinary catheter may be inserted to monitor urine output and radioactivity. Anti-nausea medication will be administered prior to treatment unless contraindicated.

The infusion process begins with amino acids, followed by the radioactive medication 30 minutes later. The infusion typically lasts 20-30 minutes, during which your vital signs will be closely monitored. After completion, you will undergo a Whole Body Scan (WBS) at the Department of Nuclear Medicine and Molecular Imaging, followed by a doctor's review.

In-Hospital Care:

During your hospital stay, you will be required to remain in your room throughout the treatment period. You may be asked to wear hospital gowns and use disposable cutlery and undergarments. Flush the toilet three times after use, and inform the nurse immediately of any urine or vomitus spillage.

Visitor Guidelines:

Visitors must report to the nurses' counter before visiting. Children and pregnant women are not allowed to visit, and all visits should be limited to 30 minutes. 

Post-Treatment Care:

After discharge, follow specific guidelines for the next few days to minimise radiation exposure to others. These include flushing the toilet twice after use, avoiding prolonged stays in public places, and maintaining distance from children under 12 and pregnant women. Avoid pregnancy for six months following treatment, and refrain from using public transportation for extended periods during the first three days post-treatment.

Follow-up Care:

A follow-up appointment will be scheduled at the Department of Nuclear Medicine and Molecular Imaging. Carry your discharge note when travelling for the next four weeks, as you may trigger radiation detection devices. Seek medical consultation if you experience fever, persistent vomiting, or any abnormal symptoms.

For more information, download our leaflet in your preferred language below: 
PPRT (Chinese).pdf